Senti Biosciences Holdings, Inc. has announced a new equity commitment agreement with CPIF II-9 Limited, aimed at securing up to $4.55 million in funding. This strategic move is designed to bolster the company’s financial position and support its ongoing growth initiatives in the biological products sector.
The agreement stipulates that the investor will purchase shares of the company’s common stock at a price determined by the Nasdaq Listing Rule 5635(d). The funding will be executed quarterly, with scheduled amounts of $1.8 million by December 31, 2026; $1.35 million by March 31, 2027; $0.5 million by June 30, 2027; $0.5 million by September 30, 2027; and $0.4 million by December 31, 2027.
Background
Senti Biosciences Holdings, Inc. operates in the biological products industry, specifically categorized under the SIC code 2836. The company is listed on the Nasdaq under the ticker symbol SNTI. It has been active in filing various forms with the SEC, including recent filings related to its financial performance and strategic agreements.
What the Filing Says
According to the recent SEC filing, the company entered into an equity commitment letter on November 9, 2026, with CPIF II-9 Limited. The filing details that the investor has committed to purchasing up to $4.55 million worth of shares, with the commitment structured to be funded quarterly.
Impact
This funding agreement is likely to have a positive impact on Senti Biosciences’ operational capabilities and financial health. The arrangement may also influence investor confidence in the company and the broader biological products industry, prompting competitors to evaluate their own funding strategies.
What's Next
The filing does not specify what happens next, but the company will proceed with the funding according to the agreed schedule. Investors and stakeholders will be watching closely for further developments.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










